Assoc.-Prof. Priv.-Doz. Dipl.-Math. oec. Dr.rer.soc.oec. Beate Jahn

Coordinator, Program Personalized and Precision Medicine

Institute of Public Health, Medical Decision Making and Health Technology Assessment, Dept. of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL – University for Health Sciences and Technology; Austria

Beate Jahn is an Associate Professor for Public Health and Data & Decision Science at UMIT TIROL, Austria, and was a visiting scholar at institutions such as Harvard T.H. Chan School of Public Health, McMaster University, University of Toronto, and BGU Israel.

Her research spans the spectrum of medical decision-making, including decision analysis, health economics, health technology assessment (HTA), quality-of-life assessment, decision aids for patient decision-making, and translating modeling results into policy and patient empowerment. She applies these methods to prevention, treatment, and disease management, with applications in cancer screening and test–treatment pathways, chronic heart failure, COVID-19 interventions, rare diseases, and patient engagement through systematic tools that deliver balanced benefit-harm and cost-effectiveness information integrating patient values and equity considerations.

Dr. Jahn has extensive practical experience collaborating with government healthcare decision-making bodies and HTA organizations in Austria, Germany, and Switzerland. She has contributed to clinical guideline development and initiatives such as the COVID-19 Future Operations Platform (FOP) and the European Commission Initiative on Colorectal Cancer (ECICC) Working Group. She is President of the Society for Medical Decision Making (SMDM) and President of the Austrian Chapter of ISPOR (International Society for Pharmacoeconomics and Outcomes Research), where she leads strategic task forces and contributes to methodological guideline development in decision analysis.

Her HTA and evaluation work includes colorectal and breast cancer screening and treatment: she has served as principal investigator of an organized screening program for Austria, co-principal investigator in EUnetHTA on genetic testing, principal investigator for the evaluation of breast cancer treatment in the Swiss context, and work-package co-lead for EUCanScreen on risk-based screening modeling. She is also a member of the International Cancer Screening Network (ICSN) and has participated in the ISPOR–SMDM Modeling Good Research Practices guideline development and the Austrian HTA Handbook.

Dr. Jahn teaches at academic institutions worldwide (Harvard/US, ERASMUS MC/NL, Munich, Berlin/Germany, Manipal/India, São Paulo/Brazil), trainings for patients, and SMDM short courses across Europe, South and North America, Asia. Dr. Jahn is a recipient of the ASPHER Early Career Excellence Award (Association of Schools of Public Health in the European Region).